We describe the model developed by two separate healthcare systems to deliver the antiamyloid therapy, lecanemab, to patients with mild cognitive impairment and mild dementia. Based on current guidelines, the experience of two separate healthcare systems that developed lecanemab clinical care delivery programs is described in detail including the development of patient eligibility criteria, cooperation with specialty services, patient monitoring, and practical steps required to safely implement lecanemab programs at a systems level. Geriatric psychiatrists have a prominent role in prescribing and monitoring antiamyloid therapy in both systems and we highlight the unique role of the geriatric psychiatrist in the future delivery of antiamyloid therapies as memory care specialists.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jagp.2025.02.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Diagnostic Communication for Alzheimer's Disease].
Brain Nerve
March 2025
Department of Dementia Medicine, Kawasaki Medical School.
The introduction of amyloid positron emission tomography and cerebrospinal fluid biomarkers, along with the advent of anti-amyloid β antibodies, has brought about significant changes in the diagnosis and treatment of dementia. Furthermore, new technologies, such as plasma biomarkers, are being developed. Therefore, it is increasingly important to accurately convey the latest and most appropriate information in daily clinical practice.
View Article and Find Full Text PDFDeveloping Treatment Models for the Delivery of the Antiamyloid Therapy, Lecanemab: Considerations for Implementation of Lecanemab in Healthcare Systems.
Am J Geriatr Psychiatry
February 2025
Department of Psychiatry and Behavioral Sciences (KGJ), Department of Neurology, Duke University School of Medicine, Durham, NC. Electronic address:
We describe the model developed by two separate healthcare systems to deliver the antiamyloid therapy, lecanemab, to patients with mild cognitive impairment and mild dementia. Based on current guidelines, the experience of two separate healthcare systems that developed lecanemab clinical care delivery programs is described in detail including the development of patient eligibility criteria, cooperation with specialty services, patient monitoring, and practical steps required to safely implement lecanemab programs at a systems level. Geriatric psychiatrists have a prominent role in prescribing and monitoring antiamyloid therapy in both systems and we highlight the unique role of the geriatric psychiatrist in the future delivery of antiamyloid therapies as memory care specialists.
View Article and Find Full Text PDFParkinsonism in Alzheimer's disease without Lewy bodies in association with nigral neuron loss: A data-driven clinicopathologic study.
Alzheimers Dement
March 2025
Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Introduction: Parkinsonism in patients with Alzheimer's disease (AD) is often attributed to Lewy-related pathology, given its high comorbidity. In the era of anti-amyloid therapy, recognizing parkinsonism caused by AD pathology is needed to optimize the treatment.
Methods: This study aimed to quantitatively characterize parkinsonism and nigral neuropathology in AD without Lewy bodies (LB).
Determinants for Substoichiometric Inhibition of IAPP and Aβ Amyloid Aggregations by Bri2 BRICHOS.
ACS Chem Neurosci
March 2025
Department of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States.
Bri2 BRICHOS, a folded domain of the transmembrane protein Bri2 expressed in both the brain and pancreas, is an experimentally known substoichiometric inhibitor of amyloid aggregation. The molecular chaperone effectively delays fibrillization at low molar ratios for both β-amyloid (Aβ) in Alzheimer's disease (AD) and islet amyloid polypeptide (IAPP) in type 2 diabetes (T2D). While discovering effective antiamyloid inhibitors that work at low doses is an appealing strategy to mitigate amyloid toxicity, the molecular mechanism underlying the broad and efficient antiamyloid activity of Bri2 BRICHOS remains unknown.
View Article and Find Full Text PDFChronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice.
J Alzheimers Dis Rep
February 2025
Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany.
Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and behavior impairments. Despite recent approvals of anti-amyloid antibodies, there remains a need for disease modifying and easily accessible therapies. Emerging evidence suggests that targeting the endocannabinoid system may hold promise for AD therapy as it plays a crucial role in different physiological processes, including learning, memory and anxiety, as well as inflammatory and immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!